Corona Vaccine Boosts Immunotherapy for Cancer Treatment
Here’s a summary of the provided text, focusing on the key findings and implications:
Key Findings:
* COVID-19 vaccines (specifically mRNA vaccines like Pfizer/BioNTech and Moderna) can substantially improve the effectiveness of immunotherapy in cancer patients. Research from the university of Texas, published in Nature, shows this correlation.
* Improved Survival Rates: Patients with advanced lung cancer who received an mRNA COVID-19 vaccine within 100 days of starting immunotherapy had a 55.7% survival rate after three years, compared to 30.8% in those who hadn’t been vaccinated.
* Mechanism: The vaccine appears to make tumors more sensitive to immunotherapy, overcoming resistance that some tumors exhibit.
* Past Context: The idea of using infections or immune stimulation to fight cancer isn’t new. Experiments with injecting dead bacteria to treat cancer date back to the late 19th century, but the underlying mechanisms are only now being understood with the advent of modern immunotherapy.
Expert Opinion:
* Immunologist Marjolein van Egmond calls the findings a “breakthrough,” stating that while the term is often overused, it’s appropriate in this case. She highlights the long-recognized connection between the immune system and cancer, and how this research builds on that understanding.
Implications:
* This research suggests a potential strategy to enhance cancer treatment by strategically combining immunotherapy with COVID-19 vaccination.
* It provides further insight into the complex interplay between the immune system, vaccines, and cancer.
The text ends mid-sentence, suggesting there’s more data about the drawbacks of immunotherapy that was not included.